Competitiveness / Health Care

This section feature research, opinion and progress reports on how the Czech Republic compares to other EU countries economically. It includes analysis of international rankings such as the WEF and World Bank.

Spotlight issue

8th October 2020 / Competitiveness / Health Care


Biontech and Pfizer initiate rolling submission to European medicines agency for SARS-COV-2 vaccine candidate BNT162b2

Rolling review accepted by the EMA based on available preclinical and clinical data for BNT162b2 to date BioNTech and Pfizer will continue regular and open dialogue with the EMA providing results from their ongoing Phase 3 study  
View more

16th September 2020 / Competitiveness / Health Care


The Do's and Don'ts of wearing a face mask

Experts agree that wearing face masks can protect people’s health and slow the spread of COVID-19. That’s because the novel coronavirus can be transmitted through respiratory droplets that get into the air from sneezing, coughing or even speaking. A mask acts as a barrier, stopping those droplets before they reach another person[1]. But a mask is only effective if it’s worn correctly. Here are the do’s and don'ts of wearing a face mask.  
View more

16th September 2020 / Competitiveness / Health Care


T-Mobile to enable free calls to 1221

Beginning September 9, T-Mobile Czech Republic will not charge any fees for calls to 1221, the information hotline of the Public Health Service of the Czech Republic. By making the line available free of charge, the operator wants to help again in the fight against the coronavirus and make the access to important information from public health authorities easier to all customers.
View more

9th September 2020 / Competitiveness / Health Care


Pfizer and Biontech to potentially supply the EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2

 The proposed agreement is intended to provide a supply of 200 million doses and an option to purchase additional 100 million doses, with deliveries starting by the end of 2020, subject to regulatory approval   The vaccine supply for the EU would be produced by BioNTech’s manufacturing sites in Germany and Pfizer’s manufacturing site in Belgium   Pfizer and BioNTech are on track to seek regulatory review of BNT162b2 as early as October 2020 and, if regulatory authorization or approval is obtained, currently plan to supply up to 100 million doses worldwide by the end of 2020 and approximately 1.3 billion doses by the end of 2021
View more

5th August 2020 / Competitiveness / Health Care


Will COVID-19 vaccines ‘save the world’?

Innovators are sprinting to develop inoculations against the novel coronavirus. Here, we summarize the latest information on research timelines and the potential impact of a vaccine on the pandemic—and society.
View more
Previous

Members of the American Chamber of Commerce in the Czech Republic